Safety
Semaglutide's thyroid warning: MTC and MEN2
A boxed warning that defines a clear group who should not use the drug.
Quick Answer
Semaglutide carries a boxed warning regarding thyroid C-cell tumors, based on findings in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Whether it causes thyroid tumors in humans is not established. Compounded semaglutide is not FDA-approved.
Key Facts
- Boxed warning: thyroid C-cell tumors seen in rodent studies
- Contraindicated with personal/family history of MTC or MEN2
- Human relevance is not established (rodent C-cells differ)
- Report a neck mass, hoarseness, trouble swallowing or shortness of breath
- Compounded semaglutide is not FDA-approved
What the label says
Like other GLP-1 drugs, semaglutide's labeling includes a boxed warning: in rodent studies, the class caused thyroid C-cell tumors. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, a genetic syndrome that raises MTC risk.
Rodents vs humans
The warning is based on rodent data. Rodent thyroid C-cells are more sensitive to this drug class than human C-cells, and whether the effect translates to humans is not established. The warning is precautionary; it does not mean the drug has been shown to cause thyroid cancer in people.
Who should avoid it
People with a personal or family history of MTC or MEN2 should not take semaglutide. Screening for this history is a standard part of evaluation before prescribing — worth checking with relatives if you are unsure of your family history.
What to watch
Labeling advises being alert to symptoms such as a neck mass, persistent hoarseness, trouble swallowing or shortness of breath, and reporting them. Routine thyroid monitoring is not generally recommended solely because of this warning. Compounded semaglutide is not FDA-approved, but the same class-based caution applies.
Frequently asked questions
Does semaglutide cause thyroid cancer?
It carries a boxed warning based on rodent studies, but whether it causes thyroid tumors in humans is not established. It is contraindicated for people with a personal or family history of MTC or MEN2.
Who should not take semaglutide?
People with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, among other contraindications a clinician will review.
References
- U.S. Food and Drug Administration. Wegovy, Ozempic and Rybelsus (semaglutide) prescribing information. Novo Nordisk.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Citations are for educational reference; this article summarizes published research in plain language and is not medical advice.
Bottom Line
Semaglutide's thyroid warning is precautionary, based on rodent data, but it defines a clear contraindication: people with a personal or family history of MTC or MEN2 should not take it.
Related from the Journal
GI side effects
The most common effects.
Pancreatitis & gallbladder
Other risks.
Hypoglycemia risk
When lows happen.